Evaluation of the concordance of ER, PR, HER2, and Ki-67 expression levels between primary breast tumors and their liver metastases: a retrospective analysis of 57 cases
Öz
Purpose: This study aims to evaluate the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression between primary breast tumors and their liver metastases.
Materials and methods: A total of 57 patients with breast cancer liver metastases were included. Immunohistochemical staining was performed to assess ER, PR, HER2, and Ki-67 expression in both primary and metastatic tumors. HER2 status was confirmed by silver in situ hybridization (SISH) when necessary. Statistical analyses were conducted to evaluate changes in biomarker expression.
Results: Comparison of biomarker expression between primary and metastatic biopsies revealed changes in ER status in 5 cases (1 from negative to positive, 4 from positive to negative); PR status in 22 cases (4 from negative to positive, 18 from positive to negative); HER2 status in 5 cases (2 from negative to positive, 3 from positive to negative); and Ki-67 status in 13 cases (6 from low to high, 7 from high to low). The discordance rates for ER, PR, HER2, and Ki-67 were calculated as 8.8%, 38.6%, 8.8%, and 28.9%, respectively.
Conclusion: Our findings confirm that biomarker expression may change between primary and metastatic breast cancer lesions. Given the crucial role of receptor status in treatment decisions, re-biopsy of metastatic lesions is essential to guide personalized therapy.
Anahtar Kelimeler
Breast cancer, estrogen receptor, progesterone receptor, HER2, discordance
Kaynakça
- Lin M, Jin Y, Lv H, Hu X, Zhang J. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. Int J Cancer. 2023;152(7):1476-1489. doi:10.1002/ijc.34365
- Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Pathol Oncol Res. 2021;27:599894. doi:10.3389/pore.2021.599894
- Shanthala S, Amirtham U, Gopal C, N SM, Jacob L, Babu G. Study of Biomarker Discordance between Primary and Recurrent Sites and its Clinical Implications in Metastatic Breast Cancer: A Single Institutional Study from India. South Asian J. Cancer 2024;13(2):90-98. doi:10.1055/s-0043-1775807
- Gogia A, Deo SVS, Sharma D, et al. Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India. J Glob Oncol. 2019;5:1-8. doi:10.1200/JGO.18.00184
- Chen R, Qarmali M, Siegal GP, Wei S. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution. Modern Pathology. 2020;33(12):2499-2506. doi:10.1038/s41379-020-0615-z
- Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277-289. doi:10.1016/j.ejca.2013.10.004
- Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. doi:10.1093/jnci/djx273
- Krøigård AB, Larsen MJ, Thomassen M, Kruse TA. Molecular Concordance Between Primary Breast Cancer and Matched Metastases. Breast J. 2016;22(4):420-430. doi:10.1111/tbj.12596
- Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34(25):3069-3103. doi:10.1200/JCO.2016.67.1487
- Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634-1657. doi:10.1093/annonc/mdy192
